Additional file 1: of Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

Tables addendum. (PDF 125 kb

Correlation between changes of plasma docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) and gene expression.

<p>Changes of plasma DHA, left, and EPA, right, and changes of expression (signal log ratio units) for the <i>ANAPC5</i> (left) and <i>CASP4</i> (right) genes.</p

Genes down-regulated by a DHA rich n-3 fatty acid or placebo supplementation.

<p>All values are means±SD.</p><p>^<i>1</i>All genes were significantly down-regulated by the n-3 FAs treatment according to SAM based on 2000 permutations and a false discovery rate of 10%, see microarray data analysis for details.</p><p>^<i>3</i>Significant and</p><p>^<i>4</i>close to significance (p = 0.06–0.09) difference in fold change between the n-3 FAs and placebo groups.</p

Genes up-regulated by a DHA rich n-3 fatty acid or placebo supplementation.

<p>All values are means±SD.</p><p>^<i>1</i>All genes were significantly up-regulated by the n-3 FAs treatment according to SAM based on 2000 permutations and a false discovery rate of 10%, see microarray data analysis for details.</p><p>^<i>2</i>We analyzed by t-test if genes regulated by n-3 FAs supplementation were also up- or down-regulated in the placebo group. The change for <i>DRG1</i> was significant (p = 0.04).</p><p>^<i>3</i>Significant and</p><p>^<i>4</i>close to significance (p = 0.05–0.06) difference in fold change between the n-3 FAs and placebo group.</p

Plasma values for docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) at baseline and after 6 months.

<p>Individual values are flanked by mean and SD values. Significant increases of DHA and EPA were noted in the n-3 fatty acids (n-3 FAs) group after 6 months, but not in the placebo group.</p

Individual messenger RNA measurements in the n-3 fatty acid group.

<p>^<i>1</i>The expression of the target gene was normalized to the LRP10 internal control using the formula 2^{(Ct target calibrator – Ct target sample)}/2^{(Ct LRP10 calibrator – Ct LRP10 sample)} where calibrator is a random sample. Subsequently, fold change was calculated as the ratio between values for 0 and 6 months of n-3 supplementation. Mean±SD values (n = 11).</p><p>^<i>4</i>Near significance.</p

CONSORT flowchart. Study design at baseline and after n-3 FA or placebo supplementation to AD patients for 6 months.

<p>AD = Alzheimer's disease, n-3 FA = Omega-3 fatty acid treatment, Placebo = Placebo treatment.</p